Characteristics of patients in whom hip joint space increased after anti-TNF-α treatment.
| Pt. | Age, yrs/Sex | BMI | Disease Duration, yrs | Peripheral Arthritis | Anti-TNF-α | Anti-TNF-α Tx. Duration, yrs | Concomitant Medication | Before/After TNF-α Blocker Therapy | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BASDAI | CRP, mg/dl | ESR, mm/h | ALP, u/l | BASRI | Average Joint Space Width, cm | ||||||||
| 1 | 30/M | 32.03 | 15 | — | IFX | 1 | Celecoxib, methylprednisolone, SSZ, MTX | 8.8/2.5 | 4.51/0.15 | 82/15 | 357/478 | 3/2 | 0.88/2.38 |
| 2 | 23/M | 24.31 | 14 | Knee | ETN | 0.8 | Naproxen, SSZ | 2.2/1.9 | 2.03/1.4 | 39/12 | 426/277 | 3/2 | 1.54/2.55 |
| 3 | 37/F | 19.6 | 18 | Knee | ETN | 3 | Celecoxib, methylprednisolone | 5.3/2.8 | 0.01/0.19 | 8/4 | 130/185 | 3/2 | 3.15/3.41 |
| 4 | 57/M | 19.55 | 23 | Ankle | ETN, ADA | 4 | Celecoxib | 6.3/2.6 | 4.5/0.12 | 120/19 | 308/365 | 3/2 | 1.28/2.49 |
| 5 | 18/M | 18.53 | 5 | — | IFX | 2 | Meloxicam, methylprednisolone, SSZ, MTX | 4.6/1 | 3.77/0.03 | 48/2 | 257/421 | 3/2 | 1.35/2.24 |
| 6 | 26/M | 24.66 | 11 | Knee | IFX | 1 | Celecoxib, SSZ | 9.6/1.4 | 4.77/0.14 | 45/2 | 302/254 | 3/2 | 1.34/2.77 |
BMI: body mass index; TNF: tumor necrosis factor; Tx.: treatment; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ALP: alkaline phosphatase; BASRI: Bath Ankylosing Spondylitis Radiology Index; SSZ: sulfasalazine; MTX: methotrexate; ETN: etanercept; IFX: infliximab; ADA: adalimumab.